At a glance
ClinicalIndex Comparison RecordN/ACompleted· 33 enrolled
Drug / intervention
Oral Contraceptive: Ortho-Novum® 1/35 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Evaluating the Effect of Oral Contraceptive Progestin Dose on Breast Epithelial Cell Proliferation
In Brief
A clinical study evaluating Oral Contraceptive: Ortho-Novum® 1/35 and Oral Contraceptive: Ovcon Fe® for Oral Contraceptive. Completed, enrolled 33 participants across 1 site.
Detailed Summary
The purpose of this research study is to gain a better understanding of the changes that may occur in the breast when a woman uses an oral contraceptive (birth control pill). Some research indicates that women who use birth control pills with lower amounts of progestin (a hormone in the birth control pill) may have lower breast cell growth than women who use birth control pills with a higher amount of progestin; this research will examine that in detail.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOral Contraceptive
CountriesUnited States
CollaboratorsUnited States Department of Defense
Timeline
N/ACompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartAug 2007
Primary CompletionNov 2008
First PostedSep 2009
TodayJul 2026
First PostedSep 7, 2009
Enrollment StartAug 1, 2007
Primary CompletionNov 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 16.8 years ago
Interventions
Oral Contraceptive: Ortho-Novum® 1/35drug
Oral Contraceptive: Ovcon Fe®drug